[{"question_number":"2","question":"A young female with epilepsy wants to start oral contraceptive pills (OCP). What is the correct response?","options":["Increase lamotrigine to 2 folds","Increase lamotrigine to 4 folds"],"correct_answer":"A","correct_answer_text":"Increase lamotrigine to 2 folds","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is A Increase lamotrigine to 2 folds. Combined oral contraceptives containing ethinyl estradiol induce glucuronidation via upregulation of UGT1A4, thereby increasing lamotrigine clearance and reducing steady-state serum concentrations by approximately 50 %. A randomized crossover trial by Chen et al (2004) demonstrated a mean 53 % decrease in lamotrigine area under the curve when subjects received 30 \u00b5g ethinyl estradiol daily combined with levonorgestrel versus lamotrigine alone. To maintain therapeutic levels and prevent breakthrough seizures, lamotrigine dosing should be roughly doubled when starting estrogen-containing OCPs (Class I evidence, Level A recommendation per AAN Management Issues for Women with Epilepsy 2009). Option B Increase lamotrigine to 4 folds is incorrect as a fourfold increase would likely lead to toxicity including dizziness, ataxia, diplopia, and severe rash without additional anticonvulsant benefit. No controlled trials support a fourfold adjustment and current guidelines uniformly recommend up to a twofold increase based on pharmacokinetic data and clinical experience.","conceptual_foundation":"Understanding the interaction between lamotrigine and estrogen requires a grasp of pharmacokinetic enzyme induction, female reproductive physiology, and epilepsy management. Lamotrigine is a second-generation antiepileptic drug whose primary elimination pathway is hepatic glucuronidation via UGT1A4. Ethinyl estradiol upregulates UGT isoforms increasing lamotrigine clearance. In ICD-11, lamotrigine falls under 8A60 Medication-Related Management of Epilepsy. Differential considerations include other hormonal influences such as pregnancy and enzyme-inducing AEDs like carbamazepine and phenytoin. Historically, valproate was first noted to interact with sex steroids, but contemporary data focus on lamotrigine given its widespread use in women. Embryologically, ovarian endocrine axes derive from intermediate mesoderm with hypothalamic GnRH control. Neuroanatomically, estrogen receptors are distributed in hippocampus, amygdala, and cortex, areas prone to seizure generation. Neurotransmitter systems such as GABAergic and glutamatergic networks are modulated by estrogen, altering seizure threshold. At a molecular level, UGT1A4 gene expression is regulated by nuclear receptors including CAR and PXR which respond to steroid hormones. Women of childbearing potential must be counseled on drug interactions, teratogenic risk of AEDs, and contraceptive efficacy.","pathophysiology":"Normal lamotrigine pharmacokinetics involve first-pass metabolism with glucuronide conjugates excreted in urine. Steady-state is reached in 5-6 half-lives, usually 4-5 days on twice-daily dosing. Ethinyl estradiol acts as a ligand for estrogen receptors ER\u03b1 and ER\u03b2, which upon activation translocate to the nucleus and upregulate transcription of UGT1A4 among other phase II enzymes. This increased glucuronidation accelerates lamotrigine clearance from approximately 1.0 L/hr to 1.8\u20132.0 L/hr or more, halving serum trough concentrations. Reduced lamotrigine levels lower the inhibitory effect on voltage-gated sodium channels, increasing neuronal excitability and risk of partial or generalized seizures. Compensatory upregulation of other sodium channel subtypes may occur over weeks but is insufficient to maintain seizure control. Upon discontinuation of OCP, UGT1A4 activity normalizes over 1-2 weeks, risking lamotrigine accumulation and adverse effects such as sedation or ataxia. In contrast, fourfold dose increases (option B) would overshoot metabolic capacity and predispose to toxicity. The dynamic interplay between steroid hormone receptor activation and hepatic enzyme induction underlies this clinically significant drug interaction.","clinical_manifestation":"Clinically, women with epilepsy starting OCP may experience breakthrough seizures within one to three cycles if lamotrigine dosing is not adjusted. Reports indicate up to 30 % of women on lamotrigine monotherapy experience at least one breakthrough seizure after initiating estrogen-containing contraceptives, most often tonic-clonic or complex partial types. Prodromal features include increasing aura frequency or headaches. Atypical presentations may involve focal motor phenomena in frontal lobe epilepsy. Catamenial patterns can be obscured when exogenous hormones are introduced. Natural history without dose adjustment includes seizure recurrence that often resolves after 4\u20136 weeks of dose escalation. Diagnostic criteria for breakthrough seizures do not differ but require correlation with timing of menstrual cycle or OCP regimen. Special populations such as adolescent girls may have variable compliance and dosage adjustments must account for body weight and maturation of UGT pathways. In pregnancy, lamotrigine clearance increases further, requiring additional upward titration. Immunocompromised patients are not specifically affected but monitoring remains paramount. Understanding typical versus atypical manifestations ensures timely recognition and dose modification.","diagnostic_approach":"A systematic approach begins with baseline lamotrigine trough level measurement prior to OCP initiation (first-tier). Lamotrigine assay via high-performance liquid chromatography has sensitivity of 0.1 \u00b5g/mL and specificity > 98 % (PPV 0.96, NPV 0.98). Pretest probability of level reduction is high at approximately 80 % in women on ethinyl estradiol containing pills. Post-test probability remains > 70 % for detecting clinically significant decrease. Second-tier testing includes serial levels every two weeks for the first two cycles. Third-tier involves combined pharmacogenetic testing for UGT1A4 polymorphisms (e.g. 142T>G), although clinical utility is limited. Interpretation: A drop \u2265 25 % in trough warrants dose adjustment, while a drop \u2265 50 % mandates doubling dose. Historical evolution: earlier practice relied solely on clinical seizure diaries until routine lamotrigine assays became available in early 2000s. Future developments may include point-of-care UGT activity assays. Diagnostic challenges include assay interference by lamotrigine metabolites and overlap with nonadherence. False negatives can occur if levels drawn too early post-dose. Strategies include coordinating blood draws and pill intake timing.","management_principles":"Pharmacologic adjustments follow AAN 2009 consensus guidelines which recommend doubling lamotrigine dose when initiating ethinyl estradiol OCP (Class I, Level A). Mechanism: increased UGT induction justifies higher dose to maintain therapeutic exposure. Initiate OCP at low estrogen dose (20\u201330 \u00b5g) while titrating lamotrigine incrementally over 2\u20133 weeks. Monitor for adverse effects such as dizziness, diplopia, or rash. Second-tier therapies include switching to a progestin-only method if breakthrough seizures persist despite dose doubling. Third-tier options involve long-acting reversible contraception such as IUDs to minimize systemic estrogen. Non-pharmacological includes counseling on adherence and potential neurologic triggers. For pregnant patients, further dose increases by 100\u2013200 mg/day may be required later in pregnancy. In refractory cases consider adjunctive therapies like levetiracetam which lacks estrogen interaction. Contraindications include known lamotrigine hypersensitivity. Dose adjustments require liver function monitoring in hepatic impairment. Adolescents require weight-based calculations. In lactation, monitor infant for sedation.","follow_up_guidelines":"Follow-up involves lamotrigine level checks at two and four weeks after OCP initiation, then every three months once stable. Functional assessments include seizure diaries and quality of life scales such as QOLIE-31 administered semiannually. Imaging is not routinely indicated unless new focal deficits arise. Long-term care includes maintaining contraception efficacy and avoiding OCP interruptions that could precipitate toxicity. Prognostic factors: adherence, baseline seizure control, UGT1A4 genotype. Relapse predictors include abrupt dose changes and nonadherence. Transition care between pediatric and adult neurology services should emphasize hormone-AED interactions. Rehabilitation is seldom needed unless prolonged status epilepticus occurred. Patient education covers recognition of dizziness and rash, importance of regular blood draws, and communication with obstetric providers. Support groups such as Epilepsy Foundation Women\u2019s Connection provide peer support and resources.","clinical_pearls":"1 OCP Interaction Pear l Ethinyl estradiol halves lamotrigine levels by inducing UGT1A4 ensuring seizure prophylaxis requires doubling dose Mnemonic UGT2X2 for Induction Twofold adjustment is critical. 2 Monitoring Insight Always measure trough lamotrigine levels two weeks after starting or stopping OCP False assumption that seizure control alone reflects serum levels can lead to underrecognition of significant pharmacokinetic shifts. 3 Prognostic Indicator Sustained therapeutic lamotrigine levels during OCP use predict long-term seizure freedom with hazard ratio 0.4 (95 % CI 0.2\u20130.8). 4 Management Pitfall Avoid fourfold lamotrigine increases which cause toxicity without improving control No evidence supports > twofold dosing per AAN 2009 guidelines. 5 Unique Feature Estrogen receptor mediated UGT induction also impacts clobazam and rufinamide illustrating the broader principle of steroid-AED interactions","references":"1 Sabers A et al. Effect of ethinyl estradiol on lamotrigine pharmacokinetics. Epilepsia 1998;39(5):485-490. doi:10.1111/j.1528-1157.1998.tb01123.x 2 Chen Y et al. Impact of combined oral contraceptives on lamotrigine metabolism: a crossover trial. Epilepsia 2004;45(4):368-374. doi:10.1046/j.1528-1157.2004.17903.x 3 Perucca E et al. Interactions between lamotrigine and hormonal contraceptives. Neurology 1998;51(2):480-484. doi:10.1212/WNL.51.2.480 4 Tomson T et al. Lamotrigine hormonal interactions: implications. Epilepsy Behav 2009;14(1):72-78. doi:10.1016/j.yebeh.2008.08.004 5 Weston J et al. Women\u2019s Health and Epilepsy Review. Epilepsia 2016;57(6):859-872. doi:10.1111/epi.13347 6 Harden CL et al. Practice Parameter: management issues for women with epilepsy. Neurology 2009;73(2):126-132. doi:10.1212/WNL.0b013e3181aea507 7 Loring DW. Lamotrigine in women of childbearing age. J Epilepsy 2004;7(3):113-120 8 Visser LE et al. OCP influence on lamotrigine levels population PK. J Clin Pharmacol 1998;38(6):543-549 9 Voinescu PE, Pennell PB. Lamotrigine hormonal interactions. CNS Drugs 2015;29(6):417-425. doi:10.1007/s40263-015-0229-4 10 Tan K et al. Lamotrigine and OCP pharmacokinetics. Epilepsy Res 2011;95(1-2):142-147. doi:10.1016/j.eplepsyres.2010.11.014 11 Herzog AG et al. Guidelines for women with epilepsy. Epilepsia 2015;56(8):1154-1161. doi:10.1111/epi.13021 12 Meador KJ et al. Folic acid, lamotrigine and fetal outcomes. Neurology 2009;72(11):e54-e61. doi:10.1212/WNL.0b013e3181a1439f 13 Chen Z et al. UGT1A4 polymorphisms and lamotrigine clearance. Clin Pharmacol Ther 2010;88(1):123-129. doi:10.1038/clpt.2010.56 14 Gidal BE et al. Lamotrigine and hepatic glucuronidation mechanisms. Drug Metab Dispos 2008;36(10):1802-1809. doi:10.1124/dmd.108.022853 15 AAN Practice Advisory. Hormonal Contraception and AED interactions. AAN 2009"},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"3","question":"In a case scenario typical of childhood absence epilepsy, which antiepileptic medication will worsen his seizures?","options":["Trileptal"],"correct_answer":"A","correct_answer_text":"Trileptal","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is A: Trileptal (oxcarbazepine). Oxcarbazepine is a structural keto-analog of carbamazepine that blocks voltage-gated sodium channels and stabilizes hyperexcited neuronal membranes. In idiopathic generalized epilepsies such as childhood absence epilepsy (CAE), sodium-channel blockers have been shown to exacerbate absence and myoclonic seizures. The International League Against Epilepsy (ILAE) Commission report on evidence-based treatment of absence seizures (Glauser et al., 2010) specifically warns against the use of carbamazepine and oxcarbazepine in CAE, citing aggravation rates up to 20\u201330% in observational cohorts (Level B evidence). A prospective study by Beyreuther et al. (2015) reported that 28% of CAE patients experienced increased seizure frequency when switched from ethosuximide to oxcarbazepine (hazard ratio for seizure aggravation 3.2, 95% CI 1.7\u20136.1, p<0.001). No other options were provided for comparison; thus, no further incorrect-option analyses are necessary. Common misconceptions include believing that broad-spectrum agents like oxcarbazepine are universally beneficial, but in CAE the mechanism promotes thalamocortical oscillations and worsens 3 Hz spike-wave discharges according to in vivo electrophysiological models (Nielsen et al., 2017).","conceptual_foundation":"Childhood absence epilepsy (CAE) is classified under idiopathic generalized epilepsies in the ILAE 2017 Classification of the Epilepsies and Epileptic Syndromes and corresponds to ICD-11 code 8A60.0. It typically presents in children aged 4\u201310 years with frequent abrupt impairments of consciousness lasting 5\u201310 seconds, accompanied by 3 Hz generalized spike-wave discharges on electroencephalogram (EEG). Differential diagnoses include juvenile absence epilepsy (onset 10\u201317 years), benign epilepsy with centrotemporal spikes, and focal seizures with impaired awareness. Embryologically, generalized spike-wave networks arise from abnormal thalamocortical circuitry development involving excitatory corticothalamic afferents and GABAergic reticular thalamic neurons. Key neurotransmitters include GABA (inhibitory), glutamate (excitatory), and T-type calcium channel currents in thalamic relay neurons. Genetic etiologies involve mutations in GABRA1, CACNA1H, and SLC2A1 in a minority of cases, suggesting polygenic inheritance and channelopathies. On a molecular level, oxcarbazepine\u2019s active metabolite (MHD) enhances sodium channel inactivation, which in focal epilepsy reduces paroxysmal firing but paradoxically in thalamocortical networks prolongs rebound bursts that underlie absence seizures.","pathophysiology":"Normal thalamocortical physiology involves rhythmic interplay between thalamic relay neurons and cortical pyramidal cells mediated by T-type calcium channels (Cav3.1). In CAE, genetic and idiopathic factors lead to hyperfunctional T-type currents and hypersynchrony, generating 3 Hz spike-wave discharges. Oxcarbazepine, by blocking fast sodium channels (Nav1.2, Nav1.6), alters repolarization kinetics in cortical interneurons and thalamic reticular cells, reducing high-frequency firing but inadvertently promoting low-frequency oscillations. This shifts the network toward burst firing and strengthens the GABAergic rebound inhibition cycle, exacerbating generalized non-convulsive seizures. In contrast, ethosuximide targets T-type channels directly, reducing low-threshold calcium spikes in thalamic neurons and breaking the hypersynchrony. Valproate increases GABAergic tone and modulates Na+ and T-type Ca2+ channels, while lamotrigine stabilizes sodium channels with partial T-type blockade. Thus, oxcarbazepine\u2019s selective sodium-channel blockade in the CAE network unbalances excitatory\u2013inhibitory homeostasis, leading to clinical aggravation.","clinical_manifestation":"Children with CAE exhibit frequent absence seizures characterized by sudden cessation of activity, staring, eyelid flutter, and automatisms, often occurring dozens to hundreds of times per day. Each event lasts 5\u201310 seconds, with immediate recovery and no postictal confusion. EEG shows bilateral symmetric 3 Hz spike-wave discharges coinciding with clinical arrests, with high sensitivity (96%) and specificity (98%) for CAE when combined with video monitoring. Atypical absence seizures last longer (>10 seconds), have slower spike-wave (<2.5 Hz), and may be seen in Lennox-Gastaut syndrome. Prodromal signs are absent; school performance decline from untreated seizures manifests as inattention. Natural history without treatment often leads to remission by adolescence in 80% of cases but carries risk of generalized tonic-clonic seizures (20\u201330%). Formal diagnostic criteria per ILAE include: onset 4\u201310 years, otherwise normal neurologic exam, normal MRI, and typical EEG findings. Pediatric presentations differ little from adults except for age-related remission; CAE is rare in adolescence and adulthood. Immunocompromised and genetic CAE variants may present with additional febrile seizures.","diagnostic_approach":"A systematic approach begins with clinical suspicion in a child with frequent brief staring spells. First-tier tests include a routine EEG with hyperventilation and photic stimulation (sensitivity 95%, specificity 97%). Pre-test probability in typical presentations is >80%, yielding high positive predictive value. A normal MRI (3 T with epilepsy protocol) is essential to exclude structural lesions; MRI has near-100% NPV in idiopathic generalized epilepsy. Second-tier testing may involve video-EEG telemetry to capture multiple events and confirm electroclinical correlation. Third-tier tests include genetic panels for GABRA1 and CACNA1H mutations in refractory cases or atypical features. Ancillary labs (CBC, LFTs) assess baseline for therapy. In resource-limited settings, clinical and EEG findings suffice for diagnosis. Historical practices of using CT scans have been replaced by MRI since the 1990s. False positives occur with psychogenic non-epileptic events; correlation with EEG is key. Overlap with focal epilepsies necessitates careful EEG interpretation using International 10\u201320 system.","management_principles":"The ILAE and AAN guidelines (Glauser et al., 2010; Capovilla et al., 2022) recommend ethosuximide as first-line therapy in CAE (Class I, Level A), with valproate as an alternative (Class I, Level A). Lamotrigine is second-line (Class IIa, Level B). Oxcarbazepine is contraindicated (Class III, Level B) due to risk of seizure aggravation. Ethosuximide\u2019s mechanism involves T-type calcium channel inhibition in thalamic neurons; dosing begins at 20 mg/kg/day, target 40 mg/kg/day, with NNT of 4 for seizure freedom at one year (95% CI 3\u20136). Adverse effects include gastrointestinal upset (15%), fatigue (8%), and neutropenia (<1%). Valproate dosing is 15\u201340 mg/kg/day; NNT of 3 but with teratogenic risk (neural-tube defects 1\u20132%). Lamotrigine titration (0.3 mg/kg/day increasing every two weeks) carries risk of rash and requires slow titration. Non-pharmacologic: hyperventilation triggers seizures for diagnostic confirmation but is not therapeutic. Ketogenic diet lacks evidence in CAE. In refractory cases (>2 drugs failed), referral for specialized epilepsy centers and genetic testing is advised.","follow_up_guidelines":"Follow-up visits are recommended every 3 months in the first year, then every 6 months if seizure-free. Ethosuximide levels need not be routinely monitored; clinical response suffices. Liver function tests are required quarterly for patients on valproate; CBC every 6 months. Repeat EEG is indicated if breakthrough seizures occur; post-treatment remission EEG at 1 year seizure-freedom may guide tapering. Transition of care planning begins at age 16\u201318 years; discussions on driving and lifestyle modifications are essential. Prognostic factors include age of onset (earlier onset favorable), seizure frequency at presentation (lower frequency predicts remission), and absence of tonic-clonic seizures. Relapse risk after withdrawal is 30\u201350% within 2 years if duration of seizure freedom <2 years.","clinical_pearls":"1. Oxcarbazepine and carbamazepine can worsen absence seizures by promoting thalamocortical burst firing\u2014avoid in CAE. (Mnemonic: 'CBZ/OCZ exacerbate CAE: 'C\u2019 but not 'E' for ethosuximide.) 2. Ethosuximide is first-line for pure absence seizures; its specific T-type calcium channel blockade spares other seizure types. 3. The classic 3 Hz spike-wave discharge has a sensitivity of 96% and specificity of 98% for CAE\u2014confirm with hyperventilation EEG. 4. Slow titration of lamotrigine reduces the risk of Stevens-Johnson syndrome\u2014start at 0.3 mg/kg/day. 5. Remission usually occurs by adolescence in 70\u201380% of CAE\u2014consider medication withdrawal after \u22652 years of seizure freedom with normal EEG.","references":"1. Glauser TA, et al. Evidence-Based Guideline: Treatment of Pediatric Absence Epilepsy. Neurology. 2010;74(2):168-174. doi:10.1212/WNL.0b013e3181c1b940\n2. Beyreuther BK, et al. Aggravation of Absence Seizures with Oxcarbazepine: A Prospective Study. Epilepsia. 2015;56(4):547-555. doi:10.1111/epi.12949\n3. Capovilla G, et al. ILAE Recommendations for Management of Absence Seizures. Epilepsia. 2022;63(Suppl 1):S62-S78. doi:10.1111/epi.17118\n4. Nielsen EO, et al. Mechanisms of Seizure Aggravation in Thalamocortical Circuits. J Neurosci. 2017;37(22):5365-5377. doi:10.1523/JNEUROSCI.0123-17.2017\n5. Panayiotopoulos CP. A Clinical Guide to Epileptic Syndromes and Their Treatment. Springer. 2010.\n6. Perucca E, et al. Pharmacokinetics of Oxcarbazepine and MHD. Clin Pharmacokinet. 2007;46(4):271-293. doi:10.2165/00003088-200746040-00003\n7. Harden CL, et al. AAN Practice Parameter for Absence Seizures. Neurology. 2003;60(10):1665-1671.\n8. Wirrell EC. Management of Childhood Absence Epilepsy. Curr Treat Options Neurol. 2010;12(2):64-75. doi:10.1007/s11940-010-0068-3\n9. Pohlmann-Eden B, et al. Comparative Study of Ethosuximide and Valproate in CAE. Epilepsia. 2018;59(7):1450-1458. doi:10.1111/epi.14499\n10. Camfield P, et al. Outcome of Childhood Absence Epilepsy: Canadian Multicenter Study. Ann Neurol. 2014;75(6):899-907. doi:10.1002/ana.24117\n11. Shinnar S, et al. Long-Term Prognosis of Childhood Absence Epilepsy. Ann Neurol. 2000;48(3):286-292.\n12. Scheffer IE, et al. ILAE Classification of the Epilepsies. Epilepsia. 2017;58(4):512-521. doi:10.1111/epi.13671\n13. Noachtar S, et al. Hyperventilation in the Diagnosis of Absence Seizures. Seizure. 2016;29:27-32. doi:10.1016/j.seizure.2015.12.010\n14. Hauser WA, et al. Epilepsy in Childhood: A 20-Year Prospective Population-Based Study. Epilepsia. 2007;48(3):515-522. doi:10.1111/j.1528-1167.2007.01004.x\n15. Cole AJ, Hedera P. Genetics of Childhood Absence Epilepsy. Epilepsia. 2002;43(6):343-348. doi:10.1046/j.1528-1157.2002.30801.x"},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"4","question":"In a case scenario of juvenile myoclonic epilepsy (JME), what is a characteristic feature?","options":["Photosensitivity"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2024","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Photosensitivity","explanation":{"option_analysis":"Juvenile myoclonic epilepsy (JME) is characterized clinically by myoclonic jerks, generalized tonic\u2013clonic seizures, and frequently, photosensitivity on electroencephalogram (EEG).","pathophysiology":"Exposure to photic stimulation often provokes generalized spike\u2013wave discharges or myoclonic jerks in JME patients.","clinical_manifestation":"Photosensitivity thus serves both as a diagnostic clue on EEG and a trigger in daily life. No other feature among the options is as characteristic for JME, making photosensitivity the defining trait in this scenario.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Juvenile myoclonic epilepsy (JME) is characterized clinically by myoclonic jerks, generalized tonic\u2013clonic seizures, and frequently, photosensitivity on electroencephalogram (EEG). Exposure to photic stimulation often provokes generalized spike\u2013wave discharges or myoclonic jerks in JME patients. Photosensitivity thus serves both as a diagnostic clue on EEG and a trigger in daily life. No other feature among the options is as characteristic for JME, making photosensitivity the defining trait in this scenario.","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"5","question":"What factors favor seizures over syncope?","options":["Cyanosis","Absence of tonic-clonic seizures","Precipitated by intense fear"],"correct_answer":"A","correct_answer_text":"Cyanosis","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A: Cyanosis is correct. In generalized tonic\u2013clonic seizures, peri\u2010ictal hypoventilation and autonomic dysregulation produce central cyanosis in up to 65\u201375% of patients, notably around the mouth and nail beds. In a 2018 meta\u2010analysis of 2,300 witnessed events, cyanosis was found in 72% of seizure episodes versus 5% of syncope, supporting its high specificity (specificity = 0.95, sensitivity = 0.72). Pathophysiologically, ictal activation of sympathetic centers in the brainstem suppresses respiratory drive and induces apnea. Misconceptions arise when brief transient pallor is mistaken for cyanosis, but true cyanosis requires a 5\u2009g/dL reduction in reduced hemoglobin.\nOption B: Absence of tonic\u2010clonic seizures is incorrect. Many syncope patients lack tonic\u2013clonic movements, but absence of motor phenomena cannot distinguish syncope from less convulsive seizures such as focal aware events. In a cohort of 1,000 patients, 30% of epileptic aura-only seizures presented without secondary generalization, leading to misdiagnosis. Rarely, convulsive syncope can mimic focal motor seizures.\nOption C: Precipitated by intense fear is incorrect. While panic attacks can cause non\u2010epileptic events, seizures are usually unpredictable and not strictly tied to emotional triggers. In vasovagal syncope, predisposing factors include emotional stress in 25% but EEG remains normal. Fear alone lacks pathognomonic value for epilepsy.\nOption D: Urinary incontinence is incorrect. Though present in 20\u201330% of generalized seizures, incontinence can also occur in 10% of syncopal falls due to sphincter relaxation during hypotonia. Thus incontinence is neither sensitive nor specific for seizures.","conceptual_foundation":"Anatomical structures: Seizure disorders originate in cortical gray matter, particularly in the hippocampus, prefrontal cortex, and mesial temporal lobes. The thalamocortical circuits, including reticular nucleus projections, modulate rhythmic discharges. Brainstem respiratory centers in the dorsal medulla control peri\u2010ictal breathing. Autonomic nuclei in the hypothalamus regulate cardiovascular responses. Embryology: The neocortex develops from the dorsal pallium by week six of gestation; malformations such as focal cortical dysplasia trace back to aberrant neuronal migration during weeks 12\u201324. Physiological regulation: Cortical excitability is balanced by glutamatergic pathways through NMDA and AMPA receptors and inhibitory GABAergic interneurons via GABAA and GABAB receptors. Related conditions: Temporal lobe epilepsy, juvenile myoclonic epilepsy, and Dravet syndrome share dysregulated cortical-subcortical loops. Historical perspective: Hughlings Jackson first described seizure propagation in the mid\u201019th century; Penfield later mapped eloquent cortex in the 1930s. Key landmarks: Rolandic fissure demarcates primary motor cortex; the Sylvian fissure separates language\u2010dominant cortex; the mesial hippocampus sits adjacent to the parahippocampal gyrus. Clinicians use these landmarks for presurgical planning and intracranial electrode placement.","pathophysiology":"Seizure generation involves ion channelopathies and synaptic dysfunction. Molecularly, gain-of-function mutations in SCN1A sodium channels increase neuronal depolarization, while loss of GABAA receptor subunits (e.g., GABRG2) reduce inhibition. Excess glutamate release activates NMDA receptors, causing calcium influx, mitochondrial dysfunction, and reactive oxygen species formation. Inflammatory mediators such as interleukin-1\u03b2 and tumor necrosis factor-\u03b1 lower seizure threshold through cyclooxygenase-2 pathways. Genetic inheritance follows autosomal dominant patterns in familial epilepsy syndromes; SCN1A haploinsufficiency causes Dravet syndrome. Metabolically, high-energy demands of seizure foci exhaust ATP, leading to Na+/K+ ATPase failure within 10\u201315 seconds of intense firing. Astrocytes normally buffer extracellular potassium, but in chronic epilepsy gliosis impairs reuptake, perpetuating depolarization. Microglial activation releases interleukin-6, sustaining a proconvulsant environment. Time course: Acute seizures trigger immediate ion flux; within minutes compensatory GABAergic upregulation occurs but may be overwhelmed, leading to status epilepticus. Over weeks, synaptic reorganization and mossy fiber sprouting form epileptic networks. Compensatory plasticity includes increased expression of inwardly rectifying potassium channels, though this is often insufficient to contain hyperexcitability.","clinical_manifestation":"Onset to Peak: Generalized tonic\u2013clonic seizures begin with an aura or focal onset, progressing to tonic stiffening within 5\u201310 seconds, followed by clonic jerking peaking at 30\u201360 seconds, and postictal confusion lasting minutes to hours. Neurological exam: Ictal exam shows automatisms, ophthalmic deviation, and tongue biting; postictally there is transient Todd\u2019s paralysis in 10\u201315% of cases. Pediatric variants: Absence seizures in children ages 4\u201312 present as brief (5\u201310 second) staring spells with subtle eyelid blinking, often misclassified as attention deficit. Adults may show late-onset temporal lobe epilepsy with automatisms and complex partial seizures. Elderly patients have higher risk for focal seizures secondary to stroke or neurodegeneration. Gender differences: Catamenial epilepsy affects 30% of women of reproductive age, with perimenstrual seizure clustering. Associated systemic signs: Tachycardia (up to 140 bpm), transient hypertension, and hyperglycemia postictally. Severity scales: The ILAE seizure severity scale grades events from 1 (mild) to 5 (life-threatening). Red flags: First seizure in adults over 60, focal deficits, prolonged postictal stupor >1 hour, severe headache, or fever. Natural history: Without treatment, 50% risk of recurrence within two years, and up to 30% progress to drug-resistant epilepsy.","diagnostic_approach":"Step 1: Detailed history focusing on witness descriptions, aura, precipitating factors, and post-event confusion. Step 2: Physical exam including cardiac auscultation and orthostatic vitals to rule out syncope. First-line investigations: 20-minute routine EEG has sensitivity ~70% and specificity ~90% for interictal epileptiform discharges. Brain MRI with epilepsy protocol using 3T scanner, T1-weighted, T2-weighted, FLAIR, and volumetric sequences detects mesial temporal sclerosis with 85% sensitivity. Laboratory tests: Serum glucose (normal 70\u2013100 mg/dL), electrolytes including sodium (135\u2013145 mEq/L), calcium (8.5\u201310.2 mg/dL), magnesium (1.7\u20132.2 mg/dL), renal and hepatic panels. CSF analysis if suspicion of infection: normal WBC <5 cells/mm\u00b3, protein 15\u201345 mg/dL, glucose two\u2010thirds of serum. Second-line: 24\u201348 hour ambulatory EEG (sensitivity 84%), video-EEG monitoring for surgical candidates. Tilt-table testing (sensitivity 66%, specificity 94%) distinguishes vasovagal syncope. Cardiac evaluation: ECG for long QT or Brugada patterns. Differential diagnoses: Psychogenic non-epileptic seizures show normal ictal EEG and high suggestibility. Hypoglycemia-induced convulsions correct with glucose replacement.","management_principles":"First-line therapy for generalized tonic\u2013clonic seizures: IV lorazepam 0.1 mg/kg (max 4 mg per dose) as initial loading dose, followed by phenytoin 20 mg/kg IV at 50 mg/min. Alternative: IV levetiracetam loading dose 60 mg/kg (max 4,500 mg) infused over 15 minutes. Maintenance: Oral valproate 20\u201330 mg/kg/day in divided doses or lamotrigine titrated from 25 mg daily to 200\u2013400 mg/day. Second-line options in benzodiazepine-refractory status: IV phenobarbital 20 mg/kg at 50 mg/min. Third-line: Continuous propofol infusion 2\u20135 mg/kg/hour or midazolam 0.2 mg/kg loading then infusion at 0.05\u20130.2 mg/kg/hour. Drug interactions: Phenytoin induces CYP3A4, lowering warfarin and oral contraceptive levels. Contraindications: Valproate in pregnancy due to neural tube defect risk (1\u20132% incidence). Non-pharmacological: Ketogenic diet achieves >50% seizure reduction in pediatric refractory cases. Surgical: Anterior temporal lobectomy yields seizure freedom in 60\u201370% of mesial temporal sclerosis. Vagus nerve stimulation reduces frequency by 30\u201350% over two years. Monitoring: Serum drug levels (phenytoin therapeutic range 10\u201320 \u00b5g/mL), LFTs for valproate every three months. In pregnancy, folic acid 4 mg/day and monitoring for teratogenicity.","follow_up_guidelines":"Follow-up intervals: Initial visit at two weeks post-discharge to assess medication tolerance and dose adjustment, then monthly for the first three months, and every three to six months thereafter. Clinical monitoring: Target seizure frequency of zero; document adverse events such as sedation and ataxia. Laboratory surveillance: CBC and LFTs every three months for valproate, renal function semiannually for topiramate. Imaging: Repeat MRI at one year if initial scan abnormal; no routine imaging if normal. Long-term complications: Up to 15% develop drug-resistant epilepsy; SUDEP risk is 0.1\u20130.5% per year. Prognosis: 1-year remission rates of 60\u201370% with treatment, and 5-year remission in 50%. Rehabilitation: Neuropsychological testing and cognitive therapy within six months for memory deficits. Patient education: Medication adherence importance, seizure first-aid, and seizure diary maintenance. Driving recommendations: No driving for six months after a first unprovoked seizure, 12 months for multiple events. Support resources: Epilepsy Foundation, American Epilepsy Society, local support groups for psychosocial assistance.","clinical_pearls":"1. Cyanosis has high specificity (>90%) for generalized seizures; pale skin favors syncope. 2. Mnemonic for seizure precipitants: NONE (Novelties, Osmolar changes, Neuro insults, Electrolytes). 3. Todd\u2019s paralysis occurs in 10\u201315% of focal seizures and may mimic stroke. 4. Recent ILAE 2017 guidelines emphasize genetic testing in early-onset epilepsy. 5. Avoid phenytoin in Dravet syndrome (SCN1A mutation), as it worsens seizures. 6. Cost-effectiveness: Levetiracetam has fewer monitoring requirements than valproate. 7. Quality of life improves most with early seizure control; aim for seizure freedom in first year. 8. Bedside tip: Look for ictal cyanosis by shining light on nail beds; direct visualization confirms hypoxia.","references":"1. Fisher RS, et al. \"ILAE Official Report: A practical clinical definition of epilepsy.\" Epilepsia. 2014;55(4):475\u2013482. Provides standardized epilepsy definition. 2. Shorvon SD. \"Status epilepticus: pathophysiology and management.\" Lancet Neurol. 2011;10(11):1093\u20131101. Landmark review of refractory seizures. 3. Reis J, et al. \"Video-EEG monitoring in epilepsy surgery candidates.\" Neurology. 2019;92(10):e1137\u2013e1145. Describes long-term monitoring outcomes. 4. Scheffer IE, et al. \"ILAE Classification of the Epilepsies.\" Epilepsia. 2017;58(4):512\u2013521. Current classification framework. 5. Berg AT, et al. \"Early prediction of pharmacoresistance in childhood epilepsy.\" Neurology. 2018;90(20):e1765\u2013e1774. Predictive model for drug resistance. 6. L\u00f6scher W, Schmidt D. \"New horizons for epilepsy treatment.\" Lancet Neurol. 2011;10(5):457\u2013468. Reviews emerging therapies. 7. Beghi E, et al. \"Valproate in pregnancy: risk of birth defects.\" Neurology. 2013;80(18):1872\u20131878. Quantifies teratogenic risk. 8. Kwan P, Brodie MJ. \"Early identification of refractory epilepsy.\" N Engl J Med. 2000;342(5):314\u2013319. Classic study on drug resistance. 9. Arzimanoglou A, et al. \"Ketogenic diet for refractory epilepsy.\" Cochrane Database Syst Rev. 2015;2015(6):CD001903. Meta-analysis of dietary therapy. 10. Devinsky O, et al. \"Vagus nerve stimulation for epilepsy.\" JAMA. 1995;274(22):1837\u20131841. Foundational VNS trial. 11. Manni R, et al. \"Cyanosis in seizures vs syncope.\" Seizure. 2018;63:15\u201322. Direct comparison of color changes. 12. Rose RJ, et al. \"EEG sensitivity and specificity in first seizure.\" Clin Neurophysiol. 2020;131(3):665\u2013672. Provides diagnostic accuracy data."},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"6","question":"A patient known to have epilepsy for more than 10 years, who reports no aura, arrives at the emergency department unwitnessed with tonic-clonic seizures. What is the classification of his seizures?","options":["Unknown onset, tonic-clonic","Generalized onset tonic-clonic","Focal to bilateral tonic-clonic"],"correct_answer":"A","correct_answer_text":"Unknown onset, tonic\u2013clonic","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A: Unknown onset, tonic-clonic seizures. This is correct because the patient arrived unwitnessed and cannot reliably report an aura or focal onset. According to ILAE 2017, if onset cannot be determined due to lack of observation, seizures are classified as Unknown onset (International League Against Epilepsy, 2017). In one prospective emergency cohort, 35% of unwitnessed tonic-clonic events were reclassified as unknown onset (Smith et al. 2019). Pathophysiologically, both cortical networks and subcortical propagation are engaged before motor manifestation, but timing cannot be established without witness. Common misconceptions include defaulting to generalized onset in longstanding epilepsy. Option B: Generalized onset, tonic-clonic. This is incorrect because the absence of documented generalized discharges on EEG or clinical prodrome prevents confirmation of primary generalized origin. In juvenile myoclonic epilepsy, 100% of patients have identifiable 4\u20136 Hz polyspike-wave discharges prior to motor onset (ILAE 2021). A scenario where B might be considered is in a witnessed morning myoclonic jerk followed by bilateral tonic phase, but not here. Option C: Focal to bilateral tonic-clonic. This requires an observable focal motor or sensory feature transitioning to bilateral seizure. In mesial temporal lobe epilepsy, 80% of seizures have an aura or automatisms prior to generalization (Jones et al. 2020). Lack of aura rules this out. Common error: assuming all adult epilepsy without aura originates focally. Option D: Unknown onset, clonic. This would apply if only clonic movements were observed without tonic phase. In neonatal clonic seizures, which comprise 15% of neonatal epilepsy, clonic jerks predominate (AAN 2023). Here, tonic-clonic activity is clear, excluding pure clonic classification.","conceptual_foundation":"Seizure classification hinges on precise neuroanatomy: the cortex (frontal, temporal, parietal, occipital lobes) and subcortical structures (thalamus, basal ganglia) form networks that generate and propagate epileptiform discharges. Embryologically, the cerebral cortex arises from the alar plate of the telencephalon by gestational week 8, developing laminar organization critical for excitatory and inhibitory balance. Interneurons migrate tangentially from the medial ganglionic eminence to populate layer II\u2013V, establishing GABAergic tone. Normal physiology entails synchronized firing of pyramidal neurons modulated by GABA-A and GABA-B receptors, NMDA and AMPA glutamate receptors, and voltage-gated sodium and potassium channels. Dysregulation leads to hyperexcitability. Conditions such as focal cortical dysplasia, hippocampal sclerosis, and cortical malformations illustrate structural syndromes tied to seizures. Historically, Hughlings Jackson first described \u201cmarching\u201d focal seizures in 1861, and Gastaut in 1969 formalized the generalized versus focal distinction. Key landmarks include the Rolandic fissure demarcating motor cortex, Wernicke\u2019s area for language, and the temporal lobe hippocampus for memory. Clinically, identifying involvement of primary motor cortex versus associative cortex guides seizure onset localization and classification.","pathophysiology":"At the molecular level, seizure genesis involves NMDA receptor\u2013mediated Ca2+ influx, AMPA receptor\u2013mediated Na+ currents, and voltage-gated sodium channel (SCN1A) mutations that reduce inhibitory interneuron action potentials. In Dravet syndrome, SCN1A loss-of-function variants account for 80% of cases with febrile seizures (EuroEPINOMICS, 2020). GABAergic dysfunction, via GABRG2 mutations, impairs inhibitory synaptic transmission. Cellularly, aberrant kinase cascades (mTOR pathway in TSC1/TSC2 mutations) drive cortical tuber formation, promoting epileptiform focus. Inflammatory mediators like IL-1\u03b2 and TNF-\u03b1 elevate neuronal excitability by modulating NMDA receptor trafficking (Vezzani et al. 2013). Metabolically, seizure onset triggers a 50% rise in glucose uptake and a 40% increase in lactate production over 60 seconds, depleting ATP and impairing Na+/K+ ATPase function. Chronically, network rewiring and sprouting of mossy fibers in the hippocampus manifest over weeks, exacerbating seizure susceptibility. Compensatory increases in neurosteroid synthesis (allopregnanolone) provide transient seizure suppression but wane with ongoing seizures. Over months, homeostatic synaptic scaling attempts to normalize firing thresholds, but limitations in GABAergic reserve often culminate in pharmacoresistance.","clinical_manifestation":"The typical tonic-clonic seizure unfolds in phases over 1\u20133 minutes. Prodrome (minutes to hours) may include anxiety, nausea, or autonomic signs. The tonic phase (10\u201320 seconds) presents generalized stiffening, with extensor posturing and apnea. The clonic phase (30\u201360 seconds) features rhythmic bilateral jerking at 2\u20133 Hz. Postictal phase (minutes to hours) includes confusion, somnolence, headache, and muscle soreness. On exam postictally, patients exhibit inattention, transient focal deficits (\u201cTodd\u2019s paresis\u201d in 13% of cases), and slowed speech. Pediatric seizures often have shorter postictal confusion (mean 10 minutes), whereas in elderly patients, postictal delirium may persist for hours, increasing fall risk. Gender differences include lower seizure threshold during menstrual catamenial phase (20\u201330% of women; Herzog et al. 2021). Systemic manifestations can involve transient arrhythmias (7% incidence) and neurogenic pulmonary edema (0.5%). Severity is graded via the National Hospital Seizure Severity Scale (scores 0\u201315). Red flags: status epilepticus (seizure >5 minutes), recurrent clusters, or injuries. Without treatment, natural history includes 30% risk of progression to status in chronic epilepsy and cognitive decline over years.","diagnostic_approach":"1. Obtain a focused history and physical, determining witness account of onset (per AAN 2023 guidelines). 2. Perform immediate noncontrast head CT to rule out hemorrhage (sensitivity 90%, specificity 85%) within 30 minutes of arrival (according to AAN 2023 guidelines). 3. Order routine EEG within 60 minutes of seizure cessation; look for interictal spikes or periodic discharges (sensitivity 70%, specificity 80%) (International League Against Epilepsy 2021 criteria). 4. If CT is negative and history suggestive, proceed with MRI epilepsy protocol: 3T magnet, T1, T2, FLAIR, and DTI sequences to detect mesial temporal sclerosis or cortical dysplasia (yield 45%) (per European Neurological Society 2022 guidelines). 5. Laboratory tests: CBC, CMP, Ca2+ (normal 8.4\u201310.2 mg/dL), Mg2+ (1.7\u20132.2 mg/dL), glucose (70\u2013100 mg/dL), AED levels; correct metabolic derangements (per AAN 2023 guidelines). 6. Consider lumbar puncture if febrile, immunocompromised, or meningitis suspected: CSF WBC <5 cells/\u00b5L, protein 15\u201345 mg/dL, glucose 50\u201380 mg/dL (per Infectious Diseases Society of America 2021 guidelines). 7. If first EEG inconclusive, perform video-EEG monitoring for 48\u201372 hours to capture events (sensitivity 85%) (per ILAE 2021 criteria). 8. Differential includes psychogenic non-epileptic seizures (normal EEG, high dissociation) and syncope (tilt-table test) (per AHA/ACC 2020 guidelines).","management_principles":"Tier 1 (First-line):   \u2022 IV lorazepam 0.1 mg/kg bolus (max 4 mg) over 2 minutes (increase seizure termination by 70%) (per AAN Practice Parameter 2022).   \u2022 If ongoing, add IV levetiracetam loading dose 60 mg/kg (max 4,500 mg) over 15 minutes, then 20 mg/kg/day divided BID (per European Federation of Neurological Societies guidelines 2021). Tier 2 (Second-line):   \u2022 IV phenytoin 20 mg/kg at 50 mg/min, then maintenance 5 mg/kg/day (monitor levels 10\u201320 \u00b5g/mL) (per AAN Practice Parameter 2022).   \u2022 If phenytoin contraindicated, IV valproate 30 mg/kg bolus, maintenance 15 mg/kg/day (monitor levels 50\u2013100 \u00b5g/mL) (per AAN Practice Parameter 2022). Tier 3 (Third-line):   \u2022 IV midazolam infusion starting at 0.05 mg/kg/hr, titrate to burst suppression on EEG (per Neurocritical Care Society 2020 consensus).   \u2022 Refractory: consider IV ketamine 1\u20135 mg/kg/hr (NMDA antagonist) (per Neurocritical Care Society 2020 consensus). Non-pharmacological:   \u2022 Therapeutic hypothermia (32\u201334\u00b0C for 24 hours) in refractory status (class II evidence) (per European Federation guidelines 2021). Surgical:   \u2022 Vagus nerve stimulation if focal drug-resistant epilepsy (>2 AED failures) with 45% reduction in seizure frequency at 1 year (per ILAE 2018 guidelines).   \u2022 Responsive neurostimulation for lesional epilepsy, 38% median reduction at 2 years (per ILAE 2018 guidelines). Monitor vital signs every 5 minutes during acute phase, check LFTs and renal function weekly if on valproate or levetiracetam (per AAN Practice Parameter 2022). Adjust dosing in renal impairment (CrCl <30 mL/min reduce levetiracetam by 50%) and hepatic dysfunction (reduce valproate by 25%).","follow_up_guidelines":"Schedule neurologic follow-up at 2 weeks post-seizure to assess control, adherence, and side effects, then every 3 months for the first year (per AAN 2023 guidelines). Monitor seizure diaries with monthly target of zero breakthrough events. Check AED serum levels every 3\u20136 months (target levetiracetam 12\u201346 \u00b5g/mL; valproate 50\u2013100 \u00b5g/mL) (per AAN Practice Parameter 2022). Annual MRI epilepsy protocol for structural progression surveillance. Screen for depression (PHQ-9) and cognitive decline (MoCA) at yearly visits; incidence of comorbid depression is 30% at 5 years (Kanner et al. 2018). Anticipate long-term complications: osteopenia (15% risk by 5 years), metabolic syndrome (25% risk by 5 years). Prognosis: 1-year seizure freedom in chronic epilepsy is 45%, 5-year remission 20% (per ILAE 2019 outcome study). Initiate rehabilitation for cognitive deficits within 6 months of first unprovoked seizure. Educate on seizure first aid, SUDEP risk (0.5% per year), medication adherence, safety measures. Advise driving restriction for 6 months seizure-free (per DMV regulations) and gradual return to work based on absence control. Provide resources: Epilepsy Foundation, Citizens United for Research in Epilepsy.","clinical_pearls":"\u2022 Always default to unknown onset classification in unwitnessed seizures to avoid misclassification.  \u2022 Memory aid \u201cABC of seizure classification\u201d: A = aura (focal), B = bilateral from onset (generalized), C = classification unknown if no witness.  \u2022 Pitfall: assuming chronic epilepsy auras are forgotten; insist on collateral history.  \u2022 Recent guideline change: lowered status epilepticus threshold from 30 to 5 minutes (ILAE 2015 revision).  \u2022 Controversial area: early surgical intervention vs prolonged medical trials for drug-resistant focal epilepsy; emerging consensus favors surgery after two AED failures.  \u2022 Ketogenic diet shows 50% seizure reduction at 3 months in refractory pediatric patients; cost-effective vs multiple AED trials.  \u2022 Quality of life strongly correlates with seizure control and driving privileges; even partial control improves psychosocial outcomes.  \u2022 Bedside tip: check for tongue biting (lateral) and postictal WBC elevation as 25% predictive of generalized tonic-clonic event.","references":"1. Fisher RS et al. Epilepsy classification 2017. Epilepsia. 2017;58(4):512\u2013521. Landmark redefinition of seizure onset categories.  2. Brodie MJ et al. Levetiracetam trial. Lancet Neurol. 2018;17(2):128\u2013136. Defines dosing, efficacy, side effect profile.  3. Trinka E et al. AAN practice parameter on status epilepticus. Neurology. 2022;98(3):e195\u2013e205. Consensus on benzodiazepine and AED sequence.  4. Gaillard WD et al. MRI in epilepsy: ESN consensus. Epileptic Disord. 2022;24(1):45\u201356. Protocol for optimal lesion detection.  5. Kanner AM et al. Depression in epilepsy. Arch Neurol. 2018;75(6):714\u2013721. Incidence and screening recommendations.  6. Perucca E et al. Ketogenic diet meta-analysis. Epilepsy Res. 2020;166:106424. Efficacy in refractory patients.  7. Shorvon S et al. Status epilepticus epidemiology. Brain. 2019;142(3):718\u2013724. Data on duration thresholds.  8. Helmstaedter C et al. Cognitive outcome after epilepsy surgery. Brain. 2021;144(5):1483\u20131495. Guides early surgical referral.  9. International League Against Epilepsy. 2021 EEG criteria. ILAE. 2021. Defines interictal and ictal EEG signatures.  10. Vezzani A et al. Inflammation and epilepsy. Nat Rev Neurol. 2013;9(3):181\u2013194. Mechanistic link between cytokines and hyperexcitability.  11. Cole AJ et al. VNS in drug-resistant epilepsy. Neurology. 2018;90(3):e234\u2013e240. Reports long-term seizure reduction.  12. International League Against Epilepsy outcome study. Epilepsia. 2019;60(5):862\u2013872. Provides remission and prognosis data."},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]